Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KPS-0373

Phase 3Small molecule

KKissei Pharmaceutical Co., Ltd.

1

Indications

5

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

DegenerationActive, not recruiting

DegenerationPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Degeneration

NCT07040137

Clinical

Trials by Indication[1]

Cerebellar Degeneration4 trials

A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT01384435·200 enrolled

A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT01004016·20 enrolled

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Completed·KKissei Pharmaceutical Co., Ltd.·Phase 3·NCT02889302·203 enrolled

Show 1 more trial

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT00863538·40 enrolled

Degeneration1 trial

Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Active, not recruiting·KKissei Pharmaceutical Co., Ltd.·Phase 3·NCT07040137·142 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for KPS-0373. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KPS-0373 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KPS-0373. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kissei Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKissei Pharmaceutical Co., Ltd.

Related News